Clinical Trials
41 trialsComparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
MK-6482-043
Merck Sharp & Dohme LLC
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
LITESPARK-029
Merck Sharp & Dohme LLC
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
STELLAR-311
Exelixis
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
ADELA
MedSIR
ACTION-1
RayzeBio, Inc.
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
M.D. Anderson Cancer Center
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
GERTRUDE
Dartmouth-Hitchcock Medical Center
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
ELEVATE
Stemline Therapeutics, Inc.
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
MOST plus
Centre Leon Berard
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
ELUMEN
Central Hospital, Nancy, France
MIDAS
University of Cincinnati
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
EVENET
AC Camargo Cancer Center
BCTOP-L-M01
Fudan University
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
BCTOP-T-M03
Fudan University
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
EVIDENT
Oslo University Hospital